Verisian

• Very small teams with minimal CDISC submission load where ROI is unlikely to justify change
• Organizations unable to change SOPs that mandate double programming
• Environments that require publicly documented security certifications prior to procurement (unless Verisian can provide documentation under NDA)

• Limited independent reviews and ratings on mainstream review platforms (G2/TrustRadius/Gartner) were found during research.
• Security and compliance certifications are not publicly documented in accessible sources reviewed.
• Pricing is not publicly disclosed, indicating reliance on demonstrations, pilots, and negotiated contracts.

• Breadth of support for diverse SAS macro frameworks and legacy code patterns
• Methodology for macro-resolved code generation and handling of edge cases
• How audit trails are stored, exported, and used in CSV validation contexts
• AI governance controls to prevent unsafe code generation or incorrect validation suggestions

• Traceability-first validation approach: ability to link code, datasets, specifications, and outputs to provide a lineage view (as described in vendor materials and conference papers).
• Integration of Pinnacle 21 outputs into a centralized issue-tracking model (per PHUSE materials), which aims to reduce fragmentation in validation message handling.

• AI-assisted validation suggestions and anomaly detection: described in vendor materials, but buyers should request demonstrations using their own studies and clear governance details.
• Operational speed claims (examples in vendor messaging) should be validated in pilot projects with measured baselines.

• Pinnacle 21: broader installed base and established validation posture for CDISC checks.
• Veeva Vault: platform breadth and enterprise standardization across clinical and regulatory workflows.

Verisian’s site includes testimonial-like claims on the vendor homepage. Example (vendor-published testimonial): "Verisian is helping us scale our statistical programming services by streamlining our clinical programming framework." These statements should be treated as vendor-published and not as independent verification.

Conference materials (PHUSE / PharmaSUG) describe workflows and product modules in a technical context, including comparisons to existing validation approaches. These materials provide insight into product design and intended operational impact but are not a substitute for independent user reviews.

• Faster root cause analysis enabled by traceability
• Reduced handoffs and spreadsheet-based issue tracking for validation messages
• More consistent submission documentation tied to a centralized code/data source of record

• Trust in AI-assisted validation and confidence scoring
• Qualification/validation burden (computer system validation) and audit readiness
• Security posture maturity (not publicly documented)
• Platform adoption friction if teams are deeply invested in existing SOPs and double-programming practices

Verisian’s homepage references a Bayer customer story. In the accessible sources collected for this report, the detailed Bayer case study page itself was not retrieved or independently confirmed. The existence and content of a Bayer–Verisian case study should be validated directly from the vendor’s referenced customer story page and, ideally, corroborated by Bayer.

Vendor messaging includes strong operational claims (for example, claims that studies can be made AI-ready quickly or that response times improve substantially). Methodology and baselines for these claims are not publicly defined in the sources reviewed and should be validated in pilots or proofs of concept.

A likely best fit includes mid-size biotech to large pharma organizations and CROs with recurring CDISC submission work. Typical teams will have dedicated statistical programming resources and multiple concurrent studies where traceability and reuse provide compounding benefits.

• Pharma, biotech, CROs
• Organizations producing SDTM/ADaM and regulatory submission packages

• Decision makers: Heads of Statistical Programming, Biostatistics leadership, Clinical Data Standards leads, Regulatory Operations/Submission leads
• End users: Statistical programmers, statisticians, data managers, medical writers, QC/QA validation staff

• Root-cause analysis across macro-heavy codebases
• Manual validation handoffs and fragmented issue tracking
• Ensuring define.xml and reviewer guides remain consistent with code and outputs

• Organization has repeatable CDISC workflows and incurs significant cost from double programming/QC
• Organization can operationalize platform output into SOPs and validation evidence
• Organization seeks improved traceability and transparency for internal review and regulator-facing readiness